CC
BDTX icon

Casdin Capital’s Black Diamond Therapeutics BDTX Stock Holding History

Casdin Capital’s Portfolio BDTX Stock Details BDTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-289,395
Closed -$9.28M – 50
2020
Q4 		$9.28M Hold
289,395
– – 0.27% 42
2020
Q3 		$8.75M Hold
289,395
– – 0.39% 38
2020
Q2 		$12.2M Hold
289,395
– – 0.72% 32
2020
Q1 		$7.22M Buy
+289,395
New +$8.81M 0.77% 34

Other funds holding BDTX

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Casdin Capital's BDTX Position: Q1 2021 in Review

Casdin Capital sold out of Black Diamond Therapeutics (BDTX) in Q1 2021, closing a stake of 289,395 shares — an estimated $9.28M sold.

Casdin Capital first reported a position in BDTX in Q1 2020 and held it in 4 quarters. The position peaked at $12.2M in Q2 2020. 113 funds tracked by Wall St. Rank hold BDTX as of Q1 2021.

  • Casdin Capital reported no remaining Black Diamond Therapeutics position as of Q1 2021 after selling out during the quarter.
  • Casdin Capital sold 289,395 Black Diamond Therapeutics shares in Q1 2021, an estimated $9.28M.
  • Casdin Capital first reported a position in Black Diamond Therapeutics in Q1 2020 and held it in 4 quarters.
  • Casdin Capital's Black Diamond Therapeutics position peaked at $12.2M in Q2 2020.
  • 113 funds tracked by Wall St. Rank held Black Diamond Therapeutics as of Q1 2021.

Based on Casdin Capital's 13F filing for Q1 2021, filed 17 May 2021.